Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 28 , ISSUE 6 ( June, 2024 ) > List of Articles

LETTER TO THE EDITOR

The Rise of Irrational Antimicrobial Combinations: Need for Clinical Jurisprudence?

Riddhi Kundu, Tanima Baronia, Prachee Sathe

Keywords : Antibiotic sensitivity, Antimicrobial agents, Multidrug resistance

Citation Information : Kundu R, Baronia T, Sathe P. The Rise of Irrational Antimicrobial Combinations: Need for Clinical Jurisprudence?. Indian J Crit Care Med 2024; 28 (6):618-619.

DOI: 10.5005/jp-journals-10071-24718

License: CC BY-NC 4.0

Published Online: 31-05-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

PDF Share
  1. Hetzler L, Kollef MH, Yuenger V, Micek ST, Betthauser KD. New antimicrobial treatment options for severe Gram-negative infections. Curr Opin Crit Care 2022;28(5):522–533. DOI: 10.1097/MCC.0000000000000968.
  2. Kundu R, Chowdhury SR. Takeaways from the recarbrio conundrum: Has the FDA jumped the gun? Indian J Microbiol 2023;63(4):702–703. DOI: 10.1007/s12088-023-01105-5.
  3. Bush K, Bradford PA. β-Lactams and β-Lactamase inhibitors: An overview. Cold Spring Harb Perspect Med 2016;6(8):a025247. DOI: 10.1101/cshperspect.a025247.
  4. Prayag PS, Patwardhan SA, Panchakshari S, Sambasivam R, Dhupad S, Soman RN, et al. Ceftazidime-avibactam with or without aztreonam vs polymyxin-based combination therapy for carbapenem-resistant Enterobacteriaceae: A retrospective analysis. Indian J Crit Care Med 2023;27(6):444–450. DOI: 10.5005/jp-journals-10071-24481.
  5. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis 2023:ciad428. DOI: 10.1093/cid/ciad428.
  6. Singh S, Sahu C, Patel SS, Singh A, Yaduvanshi N. A comparative in vitro sensitivity study of “ceftriaxone-sulbactam-EDTA” and various antibiotics against gram-negative bacterial isolates from intensive care unit. Indian J Crit Care Med 2020;24(12):1213–1217. DOI: 10.5005/jp-journals-10071-23573.
  7. Samantaray S, Kumar D, Bohra GK, Meena DS, Agarwal A, Chaudhary GR, et al. Effect of Ceftriaxone+sulbactam+disodium EDTA combination in treatment of complicated urinary tract infections caused by metallo beta-lactamase producing Enterobacterales: An open label randomized controlled trial. Open Forum Infectious Diseases 2023;10 (Supplement_2). DOI: https://doi.org/10.1093/ofid/ofad500.451.
  8. Mir MDA, Chaudhary S, Payasi A, Sood R, Mavuduru RS, Shameem M. CSE (Ceftriaxone+ Sulbactam+ Disodium EDTA) versus meropenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: PLEA, a double-blind, randomized noninferiority trial. Open Forum Infect Dis 2019;6(10):ofz373. DOI: 10.1093/ofid/ofz373.
  9. Moffatt JH, Harper M, Boyce JD. Mechanisms of polymyxin resistance. Adv Exp Med Biol 2019;1145:55–71. DOI: 10.1007/978-3-030-163 73-0_5.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.